Literature DB >> 15715937

Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells.

Li-fang Gao1, De-qi Xu, Lian-ji Wen, Xing-yi Zhang, Yue-ting Shao, Xue-jian Zhao.   

Abstract

AIM: To determine the inhibitory effect of the synthetic STAT3 siRNA on the expression of STAT3 gene in human laryngeal cancer cell lines Hep2 and to investigate the effect of STAT3 siRNA on growth and apoptosis in Hep2 cells.
METHODS: A pair of DNA templates coding siRNA against STAT3-mRNA was synthesized to reconstruct plasmid of pSilencer1.0-U6 siRNA-STAT3. Hep2 cells were transfected with RPMI-1640 media (untreated), plasmid (empty), and STAT3 siRNA, respectively. Northern blot and Western blot analysis of STAT3 and pTyr-STAT3 expression in Hep2 cells and Western blot analysis of Bcl-2 expression in the Hep2 cell was performed 72 h after transfection. MTT, flow cytometry, and AO/EB assay were used for determination of cells proliferation and apoptosis in Hep2 cells.
RESULTS: pTyr-STAT3 was markedly expressed in untreated Hep2 cells and the vector-treated Hep2 cells, whereas pTyr-STAT3 expression was significantly reduced in STAT3 siRNA-transfected Hep2 cells, indicating that STAT3 siRNA inhibited the activity of STAT3. Transfection of Hep2 cells with STAT3 siRNA significantly inhibited STAT3 expression at both mRNA and protein level in Hep2 cells and the inhibition was characterized by time-dependent transfection. Treatment of Hep2 cells with STAT3 siRNA resulted in dose-dependent growth inhibition of Hep2, this significantly increased apoptotic cell rate, and decreased Bcl-2 expression level in Hep2 cells. STAT3 siRNA had an effect on induction of either early or late stage apoptosis.
CONCLUSION: This study demonstrates that STAT3 siRNA effectively inhibits STAT3 gene expression in Hep2 cells leading to growth suppression and induction of apoptosis in Hep2 cells. The use of siRNA technique may provide a novel therapeutic approach to treat laryngeal cancer and other malignant tumors expressing constitutively activated STAT3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715937     DOI: 10.1111/j.1745-7254.2005.00053.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  22 in total

1.  MED19 promotes proliferation and tumorigenesis of lung cancer.

Authors:  Mei Sun; Rui Jiang; Jin-Dong Li; Shu-Li Luo; Hong-Wen Gao; Cheng-Yan Jin; Dong-Lei Shi; Chun-Guang Wang; Bin Wang; Xing-Yi Zhang
Journal:  Mol Cell Biochem       Date:  2011-04-26       Impact factor: 3.396

2.  Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.

Authors:  Natasa Anastasov; Margit Klier; Ina Koch; Daniela Angermeier; Heinz Höfler; Falko Fend; Leticia Quintanilla-Martinez
Journal:  J Hematop       Date:  2008-11-19       Impact factor: 0.196

3.  Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.

Authors:  Mark A Scheper; Nikolaos G Nikitakis; Risa Chaisuparat; Silvia Montaner; John J Sauk
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

4.  siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer.

Authors:  Donglei Zhou; Xun Jiang; Weixing Ding; Lijun Zheng; Lei Yang; Chengzhu Zheng; Liesheng Lu
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

5.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Authors:  Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Lack of toxicity of a STAT3 decoy oligonucleotide.

Authors:  Malabika Sen; Patricia J Tosca; Christa Zwayer; Michael J Ryan; Jerry D Johnson; Katherine A B Knostman; Patricia C Giclas; James O Peggins; Joseph E Tomaszewski; Timothy P McMurray; Changyou Li; Michael S Leibowitz; Robert L Ferris; William E Gooding; Sufi M Thomas; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-03       Impact factor: 3.333

7.  Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma.

Authors:  Tingyan Liu; Meixia Zhang; Hongliang Zhang; Chunyan Sun; Yihui Deng
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-29       Impact factor: 2.503

Review 8.  Nucleic acid-based approaches to STAT inhibition.

Authors:  Malabika Sen; Jennifer R Grandis
Journal:  JAKSTAT       Date:  2012-10-01

Review 9.  Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit.

Authors:  Daniel E Johnson
Journal:  Chin J Cancer       Date:  2012-01-17

Review 10.  The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics.

Authors:  Michalis V Karamouzis; Panagiotis A Konstantinopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.